Ascentage Pharma Announced Late Sunday A Clinical Collaboration With AstraZeneca On The Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax In Combination With BTK Inhibitor Acalabrutinib In Treatment-Naïve Patients With First-Line CLL/SLL
Portfolio Pulse from Charles Gross
Ascentage Pharma has announced a clinical collaboration with AstraZeneca to conduct a Phase III study of Bcl-2 inhibitor Lisaftoclax in combination with BTK inhibitor Acalabrutinib in treatment-naive patients with first-line CLL/SLL. The global multi-center, randomized-controlled, open-label, pivotal Phase III confirmatory trial is designed to evaluate the efficacy and safety of the combination versus immunochemotherapy.
October 16, 2023 | 8:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca is collaborating with Ascentage Pharma on a Phase III study of a drug combination for CLL/SLL treatment. This could potentially lead to a new product offering if the trial is successful.
The news of a new clinical trial is directly relevant to AstraZeneca as it is a collaboration with Ascentage Pharma. If the trial is successful, it could potentially lead to a new product offering, which could positively impact AstraZeneca's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100